Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;113(4):543-549.
doi: 10.1111/ejh.14274. Epub 2024 Jul 9.

Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation

Hafsah Chalchal  1 , Vinita Dhir  1 , Ashish Masurekar  1 , Harold Atkins  1 , Christopher Bredeson  1 , Michael Kennah  1 , Natasha Kekre  1 , David Allan  1 , Ram Vasudevan Nampoothiri  1
Affiliations

Outcomes with low dose anti-thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation

Hafsah Chalchal et al. Eur J Haematol. 2024 Oct.

Abstract

Background: Anti-thymocyte globulin (ATG) based graft versus host disease (GVHD) prophylaxis is widely used for mismatched unrelated donor allogeneic hematopoietic cell transplantation (HCT) although optimal dose remains unclear. Although recent literature suggested improved outcomes with PTCy-based regimens when compared to ATG-based regimens these studies used doses of ATG ≥5 mg/kg. Thus, we analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower-dose ATG-based regimens at our center.

Methods: We retrospectively analyzed outcomes of HLA 9/10 MMUD allogeneic HCTs using lower dose ATG-based regimens for all adults undergoing allogeneic HCT at The Ottawa Hospital from 2015 to 2022. Data regarding demographics, conditioning regimen, dose of ATG, rates of GVHD, duration of remission, and survival, were collected and analyzed.

Results: Seventy-seven (n = 77) patients (males 62.3%; median age 50 years) underwent allogeneic HCT from MMUD. Majority(81%; n = 63) received 2.5 mg/kg of rabbit ATG and remaining 18.2% (n = 14) received 4.5 mg/kg. Grade II-IV acute GVHD occurred in 24.7% (n = 19) while any chronic GVHD occurred in 32.5% (n = 25) patients. After a median follow-up of 21 months, relapse occurred in 28.6% of patients. Two-year OS, GRFS, CIR, and NRM were 60.6%, 45.3%, 16.9%, and 18.2% respectively. Dose of ATG (2.5 mg/kg vs. 4.5 mg/kg) was not associated with outcomes in either univariate or multivariate analyses.

Conclusions: When compared to published studies using ATG doses ≥5 mg/kg, GVHD prophylaxis using lower dose ATG may potentially lead to improved outcomes in patients undergoing MMUD allogeneic HCT. Further studies are needed to directly compare lower dose ATG to PTCy-based regimens to determine ideal GVHD prophylaxis for these patients.

Keywords: GVHD prophylaxis; allogeneic stem cell transplantation; low dose anti‐thymocyte globulin; mismatched unrelated donor.

PubMed Disclaimer

References

REFERENCES

    1. Passweg JR, Baldomero H, Chabannon C, et al. Hematopoietic cell transplantation and cellular therapy survey of the EBMT: monitoring of activities and trends over 30 years. Bone Marrow Transplant. 2021;56(7):1651‐1664.
    1. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem‐cell grafts in the U.S. registry. N Engl J Med. 2014;371(4):339‐348.
    1. Beatty PG, Mori M, Milford E. Impact of racial genetic polymorphism on the probability of finding an HLA‐matched donor. Transplantation. 1995;60(8):778‐783.
    1. Walker I, Panzarella T, Couban S, et al. Pretreatment with anti‐thymocyte globulin versus no anti‐thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open‐label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164‐173.
    1. Finke J, Bethge WA, Schmoor C, et al. Standard graft‐versus‐host disease prophylaxis with or without anti‐T‐cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open‐label, multicentre phase 3 trial. Lancet Oncol. 2009;10(9):855‐864.

MeSH terms

Substances